Evaluation of Novel Renal Biomarkers with a Cisplatin Model of Kidney Injury: Gender and Dosage Differences

Toxicologic Pathology

Volumn 40, Issue 3, 2012, Pages 522-533

  Pinches, M ^a   Betts, C ^a   Bickerton, S ^a   Burdett, L ^a   Thomas, H ^a   Derbyshire, N ^a   Jones, H B ^a   Moores, M ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

biomarkers; clinical pathology; preclinical research and development; renal; safety assessment; toxicologic pathology

Indexed keywords

BIOLOGICAL MARKER; CISPLATIN; CREATININE; CYSTATIN C; UREA; ALBUMIN; ANTIGEN; GLUCOSE; GLUTATHIONE S-TRANSFERASE YB1; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE ALPHA; KIDNEY INJURY MOLECULE 1; N ACETYL BETA GLUCOSAMINIDASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; OSTEOPONTIN; PROTEIN; RENAL PAPILLARY ANTIGEN 1; UNCLASSIFIED DRUG;

ANIMAL; ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; CHEMISTRY; CYTOCHEMISTRY; DISEASE MODEL; DOSE RESPONSE; FEMALE; KIDNEY; KIDNEY DISEASE; MALE; METABOLISM; PATHOLOGY; RAT; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SEX DIFFERENCE; URINE; WISTAR RAT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; BLOOD SAMPLING; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DRUG MEGADOSE; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; HISTOPATHOLOGY; INJURY SEVERITY; KIDNEY INJURY; KIDNEY TUBULE NECROSIS; LOW DRUG DOSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RAT MODEL; SINGLE DRUG DOSE; UREA BLOOD LEVEL; URINALYSIS;

ANIMALS; BIOLOGICAL MARKERS; CISPLATIN; CREATININE; CYSTATIN C; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HISTOCYTOCHEMISTRY; KIDNEY; KIDNEY DISEASES; MALE; RATS; RATS, WISTAR; REFERENCE VALUES; ROC CURVE; SEX FACTORS; UREA;

EID: 84867468734     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623311432438     Document Type: Review

References (19)

1. Benöhr P. Grenz A. Hartmann J. T. Müller G. A. Blaschke S. (2006). Cystatin C—a marker for assessment of the glomerular filtration rate in patients with cisplatin chemotherapy. Kidney Blood Press Res 29(1), 32–5.
2. Bonventre J. (2010).“Mechanisms of Acute kidney Injury and Repair.” In Management of Acute Kidney Problems, Vol. 35. Chap 2.1, 13–19. Springer: Berlin Heidelberg
3. DeLong E. R. DeLong D. M. Clarke-Pearson D. L. (1988). Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44, 837–45.
4. Dieterle F. Sistare F. Goodsaid F. Papaluca M. Ozer J. S. Webb C. P. Baer W. Senagore A. Schipper M. J. Vonderscher J. Sultana S. Gerhold D. L. Phillips J. A. Maurer G. Carl K. Laurie D. Harpur E. Sonee M. Ennulat D. Holder D. Andrews-Cleavenger D. Gu Y. Z. Thompson K. L. Goering P. L. Vidal J. M. Abadie E. Maciulaitis R. Jacobson-Kram D. Defelice A. F. Hausner E. A. Blank M. Thompson A. Harlow P. Throckmorton D. Xiao S. Xu N. Taylor W. Vamvakas S. Flamion B. Lima B. S. Kasper P. Pasanen M. Prasad K. Troth S. Bounous D. Robinson-Gravatt D. Betton G. Davis M. A. Akunda J. McDuffie J. E. Suter L. Obert L. Guffroy M. Pinches M. Jayadev S. Blomme E. A. Beushausen S. A. Barlow V. G. Collins N. Waring J. Honor D. Snook S. Lee J. Rossi P. Walker E. Mattes W. (2010). Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium. Nat Biotechnol 28(5), 455–62.
5. EMA Committee for Medicinal Products for Human Use (30 April 2010). Consultation on the Qualification Opinion ILSI/HESI. Submission of Novel Renal Biomarkers for Toxicity. EMA/283298/2010, European Medicine Agency.
6. Garrett M. D. Workman P. (1999). Discovering novel chemotherapy drugs for the third millennium. Eur J Cancer 35, 2010–30.
7. Han W. K. Bailly V. Abichandavi R. (2002). Kidney injury molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int 62, 237–44.
8. Jordan P. Carmo-Fonseca M. (2000). Molecular mechanisms involved in cisplatin cytotoxicity. Cellular and Molecular Life Sciences 57, 1229–35.
9. Kola I. Landis J. (2004). Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov, 3, 711–716.
10. Lesco L. K. Atkinson A. J., Jr (2001). Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Ann Rev Pharmacol Toxicol 41, 347–66.
11. Ozer J. S. Dieterle F. Troth S. Perentes E. Cordier A. Verdes P. Staedtler F. Mahl A. Grenet O. Roth D. R. Wahl D. Legay F. Holder D. Erdos Z. Vlasakova K. Jin H. Yu Y. Muniappa N. Forest T. Clouse H. K. Reynolds S. Bailey W. J. Thudium D. T. Topper M. J. Skopek T. R. Sina J. F. Glaab W. E. Vonderscher J. Maurer G. Chibout S. D. Sistare F. D. Gerhold D. L. (2010). A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function. Nat Biotechnol 28(5), 486–94.
12. Pinches M. D. Betts C. J. Bickerton S. J. Beattie L. Burdett L. D. Thomas H. T. Derbyshire N. A. Moores M. Price S. A. (2012a). Evaluation of novel renal biomarkers with a cisplatin model of kidney injury: methodology and reference ranges. Toxicol Pathol 40(3), 524–39.
13. Pinches M. D. Betts C. J. Bickerton S. J. Beattie L. Burdett L. D. Thomas H. T. Derbyshire N. A. Moores M. (2012b). Evaluation of novel urinary renal biomarkers with a cisplatin model of kidney injury: Effects of collection period. Toxicol Pathol 40(3), 524–30.
14. Pruefer F. G. Lizarraga F. Maldonado V. Melendez-Zajgla J. (2008). Participation of Omi Htra2 serine-protease activity in the apoptosis induced by cisplatin on SW480 colon cancer cells. J Chemother 20(3), 348–54.
15. Star R. A. (1998). Treatment of acute renal failure. Kidney Int 54, 1817–31.
16. Trzaska S. (20 June 2005). Cisplatin. C&EN News 83(25). Available at http://pubs.acs.org/cen/coverstory/83/8325/8325cisplatin.html.
17. Warnock D. Peck C. (2010). A roadmap for biomarker qualification. Nature Biotechnology 28, 444–5.
18. Yao X. Panichpisal K. Kurtzman N. Nugent K. (2007). Cisplatin nephrotoxicity: a review. Am J Med Sci 334(2), 115–24.
19. Yonezawa A. Masuda S. Nishihara K. Yano I. Katsura T. Inui K. (2005). Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. Biochem Pharmacol 70(12), 1823–31.